TTK Healthcare Limited has informed the Exchange about General Updates
TTKHLTCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Microcap 250 and 2.1 pts more than its Diversified peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
TTK Healthcare's Board approved audited financial results for Q4 and FY ended March 31, 2025 with an unmodified auditor opinion from PKF Sridhar & Santhanam LLP. Revenue from Operations grew to Rs. 80,149 lakhs from Rs. 75,279 lakhs in FY24 (up ~6.5%), while Profit After Tax jumped to Rs. 8,166 lakhs from Rs. 6,284 lakhs (~30% growth), boosted by a net Rs. 1,391 lakhs of exceptional items – a Rs. 1,977 lakh profit on sale of leasehold land at Mahindra World City, Chennai, partly offset by a Rs. 586 lakh write-off of USAID-bound contraceptive inventory in the Protective Devices division. EPS rose to Rs. 57.79 from Rs. 44.47. The Board recommended a 100% dividend (Rs. 10 per share) and fixed the 67th AGM for July 25, 2025. M/s Geeyes & Co. was appointed as Cost Auditor for FY26.
Strong ~30% PAT growth and a full 100% dividend are positive for shareholders. However, the headline PAT is materially aided by the one-time land sale gain, and net operating cash flow turned negative at Rs. (398) lakhs due to high tax outflows, so investors should focus on the underlying pre-exceptional earnings power (PBT before exceptionals up ~12%) for a cleaner read on sustainable profitability.